Analytical Data
-
基因名
FAM132A
- Application
-
别名
C1QDC2; C1QTNF12; Adipolin; Adipose-derived insulin-sensitizing factor; Complement C1q tumor necrosis factor-related protein 12
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5T7M4
-
表达区间
Gly92~Gln241
-
分子量
16kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FAM132A, also known as FAM132A/FBXL20, is a recently identified gene that encodes a protein implicated in various cellular processes, including metabolism and immune responses. Research has shown that FAM132A may play a crucial role in the regulation of fat metabolism and inflammatory responses, linking it to conditions such as obesity and metabolic syndrome. The protein's function and mechanisms of action remain largely unexplored, making it an attractive target for further investigation. Recombinant FAM132A protein offers a valuable tool for studying its biological functions in detail, including interactions with other proteins and pathways involved in lipid metabolism and inflammation. Understanding the role of FAM132A could potentially reveal new therapeutic targets for metabolic disorders and improve our overall comprehension of metabolic regulation. Recent advancements in recombinant protein technology have enabled researchers to produce FAM132A in vitro, allowing for detailed functional assays and characterization that may shed light on its significance in human health. Continued research on FAM132A will contribute to the broader field of metabolic research, potentially leading to innovative strategies for managing and treating related diseases.
